BullFrog AI Announces Licensing Agreement with Johns Hopkins University for Oncology Asset
April 18 2023 - 6:00AM
BullFrog AI Holdings, Inc. (Nasdaq: BFRG) ("Bullfrog AI" or the
"Company"), a digital technology company using machine learning to
usher in a new era of precision medicine, today announced an
exclusive license agreement with Johns Hopkins University for
prodrug compositions of mebendazole. The exclusive license was
signed on October 13, 2022.
The world-wide, royalty-bearing
license includes the rights to commercialize N-substituted
prodrugs of mebendazole that demonstrate improved solubility and
bioavailability relative to the parent compound. The license
covers prodrug compositions and use for treating disease as claimed
in multiple US and worldwide patent applications.
"This asset is another key addition to our
oncology development pipeline and provides us with an opportunity
to demonstrate how our AI/ML technology can turn promising drug
candidates into tangible therapies in a cost-effective and
efficient manner," said BullFrog AI’s founder and CEO, Vin Singh,
"We are extremely proud of our expanding relationship with Johns
Hopkins. We look forward to working with strategic partners to
advance the development and monetize this promising asset for the
treatment of glioblastoma and possibly additional oncology
indications."
About BullFrog AI
BullFrog AI is a digital technology company
using machine learning to usher in a new era of precision medicine.
Through its collaborations with leading research institutions,
including Johns Hopkins University, BullFrog AI is at the forefront
of AI-driven drug development. Using its proprietary bfLEAP™
artificial intelligence platform, BullFrog AI aims to enable the
successful development of pharmaceuticals and biologics by
predicting which patients will respond to therapies in development.
BullFrog AI is deploying bfLEAP™ for use at several critical stages
of development with the intention of streamlining data analytics in
therapeutics development, decreasing the overall development costs
by decreasing failure rates for new therapeutics, and impacting the
lives of countless patients that may have otherwise not received
the therapies they need.
For more information visit BullFrogAI at
Website: www.bullfrogai.com
LinkedIn: https://www.linkedin.com/company/bullfrogai/
Safe Harbor Statement
This press release contains forward-looking
statements. We base these forward-looking statements on our
expectations and projections about future events, which we derive
from the information currently available to us. Such
forward-looking statements relate to future events or our future
performance, including: our financial performance and projections;
our growth in revenue and earnings; and our business prospects and
opportunities. You can identify forward-looking statements by those
that are not historical in nature, particularly those that use
terminology such as "may," "should," "expects," "anticipates,"
"contemplates," "estimates," "believes," "plans," "projected,"
"predicts," "potential," or "hopes" or the negative of these or
similar terms. In evaluating these forward-looking statements, you
should consider various factors, including: our ability to change
the direction of the Company; our ability to keep pace with new
technology and changing market needs; and the competitive
environment of our business. These and other factors may cause our
actual results to differ materially from any forward-looking
statement. Forward-looking statements are only predictions. The
forward-looking events discussed in this press release and other
statements made from time to time by us or our representatives, may
not occur, and actual events and results may differ materially and
are subject to risks, uncertainties, and assumptions about us. We
are not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
Media Contacts:
Bullfrog AI
Dave GentryRedChip Companies,
Inc.BFRG@redchip.com800-733-2447
SOURCE: BullFrog AI Holdings,
Inc.
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Jul 2023 to Jul 2024